PD173074

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (11)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–11 of 11 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR1 Expression1
Dovitinib + PD173074

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

BAIAP2L1 Fusion1
PD173074	Bladder Carcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID144 Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and incre… (full text at CIViC) PMID 23558953 · Wu et al., 2013 · Open in CIViC	civic

FGFR3 Overexpression1
Dovitinib + PD173074 + Tyrosine Kinase Inhibitor SU5402Substitutes	Bladder Carcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID803 The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression. PMID 21119661 · Lamont et al., 2011 · Open in CIViC	civic

AHCYL1 Fusion1
Infigratinib + PD173074Substitutes	Cholangiocarcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID1853 Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ39… (full text at CIViC) PMID 24122810 · Arai et al., 2014 · Open in CIViC	civic

BICC1 Fusion1
Infigratinib + PD173074Substitutes	Cholangiocarcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID1851 Expression of the FGFR2-BICC1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398… (full text at CIViC) PMID 24122810 · Arai et al., 2014 · Open in CIViC	civic

FGFR3 G691R1
Infigratinib + PD173074Substitutes	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	4	submitted	EID4870 FGFR3 G691R mutations were found in ~5.5% of lung adenocarcinoma patients using NGS and mass-spectrometry. The mutation was further found to transform NIH-3T3 cells and form tumors upon xenotransplant… (full text at CIViC) PMID 27998968 · Chandrani et al., 2017 · Open in CIViC	civic

FGFR3 S249C1
Infigratinib + PD173074Substitutes	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID4871 In this study, 363 lung adenocarcinoma tumors of Indian origin were analyzed using targeted next-generation sequencing and mass spectrometry genotyping, and FGFR3 mutations were identified in 20 tumor… (full text at CIViC) PMID 27998968 · Chandrani et al., 2017 · Open in CIViC	civic

FGFR1 Amplification2
PD173074	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID686 Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line. PMID 21666749 · Dutt et al., 2011 · Open in CIViC	civic
〃	Lung Squamous Cell Carcinoma	Predictive	D	Supports Sensitivity Response	5	accepted	EID680 Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were hig… (full text at CIViC) PMID 21160078 · Weiss et al., 2010 · Open in CIViC	civic

FGFR2 N550K1
PD173074	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1322 The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wi… (full text at CIViC) PMID 18757403 · Byron et al., 2008 · Open in CIViC	civic

FGFR3 V555M1
AZ12908010 + Fexagratinib + PD173074Substitutes	Myeloid Neoplasm	Predictive	D	Supports Resistance	2	accepted	EID6408 Preclinical study of FGFR Inhibitors AZ12908010, PD173074 and AZD4547 in cancer cell lines. Cell lines with aberrant FGFR signalling were more sensitive to FGFR Inhibition. Sequencing of a myeloma cel… (full text at CIViC) PMID 22869148 · Chell et al., 2013 · Open in CIViC	civic